Avidity Biosciences (RNA) Price & Analysis

Compare

1,078 Followers

RNA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$21.51 - $56.00

Previous CloseN/A

Volume185.29K

Average Volume (3M)4.05M

Market Cap

$5.78B

Enterprise Value$2.50B

Total Cash (Recent Filing)$1.18B

Total Debt (Recent Filing)$5.13M

Price to Earnings (P/E)―

Beta1.83

Next Earnings

Nov 11, 2025

EPS Estimate

-1.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.21

Shares Outstanding143,653,340

10 Day Avg. Volume5,382,901

30 Day Avg. Volume4,048,395

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue233.32

Enterprise Value/Gross Profit252.47

Enterprise Value/Ebitda-4.82

Forecast

1Y Price Target

$68.73

Price Target Upside65.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

Bulls Say, Bears Say

Bulls Say

Financial PositionWith ~$1.2B cash in the coffers, Avidity plans to file three biologics licensing applications (BLA) within 12 months and expects to self-commercialize the drugs in the U.S., EU and Japan.

Market GrowthThe company is preparing for three potential drug launches, which could significantly enhance its market presence.

Platform PotentialAvidity's antibody-oligonucleotide (AOC) platform is designed to overcome biological barriers to deliver genetic medicines that have the potential to stop or reverse neuromuscular disorders.

Bears Say

Regulatory ChallengesThe EMA is unlikely to grant conditional approval without functional data, requiring a confirmatory global Phase 3 trial.

Safety ConcernsSafety remains favorable, with only one drug-related serious adverse event reported.

Avidity Biosciences News

Netflix upgraded, Five Below initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1d ago

Avidity Biosciences initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Avidity Biosciences (RNA) with a Buy rating and $62 price target The company...

1d ago

RNA

Avidity Biosciences falls -8.2%

Avidity Biosciences (RNA) is down -8.2%, or -$3.66 to $41.08. Published first on TheFly – the ultimate source...

3d ago

RNA

Avidity Biosciences falls -5.4%

Avidity Biosciences (RNA) is down -5.4%, or -$2.41 to $42.33. Published first on TheFly – the ultimate source...

3d ago

RNA

3 Best Stocks to Buy Now, 9/15/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3d ago

RNA

Avidity Biosciences price target raised to $65 from $56 at BofA

BofA raised the firm’s price target on Avidity Biosciences (RNA) to $65 from $56 and keeps a Buy...

4d ago

RNA

Avidity Biosciences price target raised to $87 from $68 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avidity Biosciences (RNA) to $87 from $68 and keeps a...

6d ago

RNA

Avidity Biosciences 15M share Secondary priced at $40.00

The deal size was increased to $600M from $500M and priced below last closing price of $41.04. Leerink,...

7d ago

RNA

Kroger reports mixed Q2, U.S. CPI rises 0.4% in August: Morning Buzz

The major averages were broadly higher near noon following U.S. CPI data that could potentially influence the Federal...

7d ago

CNC

Avidity Biosciences falls -18.2%

Avidity Biosciences (RNA) is down -18.2%, or -$8.44 to $37.96. Published first on TheFly – the ultimate source...

7d ago

RNA

Avidity Biosciences falls -19.5%

Avidity Biosciences (RNA) is down -19.5%, or -$9.06 to $37.34. Published first on TheFly – the ultimate source...

7d ago

RNA

Avidity Biosciences Announces Major Stock Offering

Avidity Biosciences ( ($RNA) ) has provided an announcement. On September 11, 2025, Avidity Biosciences announced an underwriting...

6d ago

RNA

Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion

Goldman Sachs analyst Corinne Johnson maintained a Buy rating on Avidity Biosciences yesterday and set a price target...

7d ago

RNA

Avidity Biosciences’ Del-Zota Shows Promising Data in DMD, Justifying Buy Rating and $56 Price Target

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on RNA stock, giving a Buy...

8d ago

RNA

RNA FAQ

What was Avidity Biosciences Inc’s price range in the past 12 months?

Avidity Biosciences Inc lowest stock price was $21.51 and its highest was $56.00 in the past 12 months.

What is Avidity Biosciences Inc’s market cap?

Avidity Biosciences Inc’s market cap is $5.78B.

When is Avidity Biosciences Inc’s upcoming earnings report date?

Avidity Biosciences Inc’s upcoming earnings report date is Nov 11, 2025 which is in 54 days.

How were Avidity Biosciences Inc’s earnings last quarter?

Avidity Biosciences Inc released its earnings results on Aug 07, 2025. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$0.958 by -$0.252.

Is Avidity Biosciences Inc overvalued?

According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avidity Biosciences Inc pay dividends?

Avidity Biosciences Inc does not currently pay dividends.

What is Avidity Biosciences Inc’s EPS estimate?

Avidity Biosciences Inc’s EPS estimate is -1.13.

How many shares outstanding does Avidity Biosciences Inc have?

Avidity Biosciences Inc has 143,653,340 shares outstanding.

What happened to Avidity Biosciences Inc’s price movement after its last earnings report?

Avidity Biosciences Inc reported an EPS of -$1.21 in its last earnings report, missing expectations of -$0.958. Following the earnings report the stock price went down -2.588%.

Which hedge fund is a major shareholder of Avidity Biosciences Inc?

Currently, no hedge funds are holding shares in RNA

Avidity Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.76%

Trailing 12-Months

Asset Growth

1.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences (RNA) Earnings & Revenues

Historic Earnings Reports

RNA Stock 12 Month Forecast

Average Price Target

$68.73

▲(65.85% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","43":"$43","61":"$61","79":"$79","97":"$97"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.73,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.73</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,43,61,79,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.23,50.981538461538456,54.73307692307692,58.48461538461538,62.23615384615384,65.9876923076923,69.73923076923077,73.49076923076923,77.24230769230769,80.99384615384615,84.74538461538461,88.49692307692308,92.24846153846153,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.23,48.88384615384615,50.5376923076923,52.19153846153846,53.84538461538462,55.49923076923077,57.153076923076924,58.80692307692308,60.46076923076923,62.11461538461539,63.76846153846154,65.4223076923077,67.07615384615386,{"y":68.73,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.23,47.596923076923076,47.96384615384615,48.33076923076923,48.69769230769231,49.06461538461538,49.43153846153846,49.79846153846154,50.16538461538462,50.53230769230769,50.89923076923077,51.26615384615385,51.63307692307692,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >